Polar Asset Management Partners’s Olema Pharmaceuticals OLMA Stock Holding History

Polar Asset Management Partners’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,400	Closed	-$119K	–	678
2024 Q4	$119K	Buy	+20,400	New	+$204K	﹤0.01%	513
2023 Q3	–	Sell	-134,500	Closed	-$1.21M	–	946
2023 Q2	$1.21M	Buy	+134,500	New	+$812K	0.02%	494

Other funds holding OLMA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LMC

Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return

Polar Asset Management Partners's OLMA Position: Q1 2025 in Review

Polar Asset Management Partners sold out of Olema Pharmaceuticals (OLMA) in Q1 2025, closing a stake of 20,400 shares — an estimated $119K sold.

Polar Asset Management Partners first reported a position in OLMA in Q2 2023 and held it in 2 quarters. The position peaked at $1.21M in Q2 2023. 133 funds tracked by Wall St. Rank hold OLMA as of Q1 2025.

Polar Asset Management Partners reported no remaining Olema Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Polar Asset Management Partners sold 20,400 Olema Pharmaceuticals shares in Q1 2025, an estimated $119K.
Polar Asset Management Partners first reported a position in Olema Pharmaceuticals in Q2 2023 and held it in 2 quarters.
Polar Asset Management Partners's Olema Pharmaceuticals position peaked at $1.21M in Q2 2023.
133 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2025.

Based on Polar Asset Management Partners's 13F filing for Q1 2025, filed 15 May 2025.